Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Phase 1/2, multi-center, randomized, double-blind, multiple ascending dose,
placebo-controlled study that enrolled 36 subjects with mitochondrial myopathy associated
with genetically confirmed mitochondrial disease to evaluate the safety, tolerability,
pharmacokinetics (PK), and preliminary efficacy of MTP-131 in this patient population.